In gemcitabine-induced myelosuppression mice, DGBX decoction enhances the anti-cancer effect of gemcitabine by regulating the expression of stress response protein Hu antigen R (HuR), deoxycytidine kinase (dCK), and nuclear factor erythroid 2-related factor (Nrf2). This evidence concerns the gene ELAVL1 and cancer.